One-Shot radiation for recurrent prostate cancer: game changer or risky bet?

NCT ID NCT06941363

Recruiting now Disease control Sponsor: University of Milano Bicocca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a single, very high dose of radiation (17 Gy) to the prostate area in men whose prostate cancer has come back after surgery. The goal is to see if this precise, one-time treatment can control the cancer while reducing side effects. Fifty men will be enrolled, and researchers will track side effects and quality of life for up to 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: single high-dose radiation therapy (17 Gy) to the prostate bed
What this could lead to: If successful, this could offer a shorter, more precise radiation option for men whose prostate cancer returns after surgery, potentially with fewer side effects.
What could go wrong: This is a small, early-phase study with only 50 participants, so results may not apply to everyone. The high single dose may still cause bladder or bowel side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (POST PROSTATECTOMY)

Contacts and locations

Locations

Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori (University of Milan Bicocca)
RECRUITING

Monza, Italy, 20900, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.